Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

A Novel Prognostic Model for Patients with Acute Myeloid Leukemia in First Relapse with Improved Prognostic Accuracy

Niek G. Van Der Maas, Dimitri Breems, Clara Klerk, Thomas Pabst, Patrycja Gradowska, Bart J. Biemond, Jurgen Kuball, Janine Van Elssen, Otto Visser, Marie-Christiane Vekemans, Carlos Graux, Johan Maertens, H. Berna Beverloo, Peter J. M. Valk, Gert J. Ossenkoppele, Bob Lowenberg, Geert A. Huls, Jan J. Cornelissen, Jurjen Versluis

Blood (2023) 142 (Supplement 1): 724.

https://doi.org/10.1182/blood-2023-180812

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Vexas Syndrome: Results of a Multicenter Study from the Chronic Malignancies and Autoimmune Disease Working Parties of the EBMT

Blood (2023) 142 (Supplement 1): 708.

https://doi.org/10.1182/blood-2023-174385

Published: 2023

Journal Articles

Interindividual HLA Evolutionary Divergence in Single HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation for Malignant Hematological Disorders: A Report on Behalf of the Cellular Therapy and Immunobiology Working Party of the EBMT

Blood (2023) 142 (Supplement 1): 895.

https://doi.org/10.1182/blood-2023-187622

Published: 2023

Journal Articles

Improved Gvhd-Relapse Free Survival of Ex Vivo αβtcr/CD19 Depleted Allo-Sct Combined with In Vivo T Cell Depletion with ATG When Compared to T Cell Replete Transplantations with or without the Addition of ATG

Moniek De Witte, Anniek Stuut, Klaartje Nijssen, Lotte Van Der Wagen, Anna Van Rhenen, Laura Daenen, Anke Janssen, Henk-Jan Prins, Kasper Westinga, Julia Drylewicz, Jurgen Kuball

Blood (2023) 142 (Supplement 1): 4931.

https://doi.org/10.1182/blood-2023-173621

Published: 2023

Journal Articles

Long Term Outcomes and Renal Response Following Autologous Stem Cell Transplantation for Light Chain Deposition Disease:a Retrospective Study on Behalf of the Cmwp of the EBMT

Blood (2023) 142 (Supplement 1): 3403.

https://doi.org/10.1182/blood-2023-184367

Published: 2023

Journal Articles

First in Human Clinical Responses and Persistence Data on TEG001: A Next Generation of Engineered Αβ T Cells Targeting AML and MM with a High Affinity γ9δ2TCR

Moniek de Witte, Jojanneke Scheepstra, Naomi Weertman, Annet Daudeij, Lotte van der Wagen, Rimke Oostvogels, Colin de Haar, Henk-Jan Prins, Willem Dohmen, Carly Bartels-Wilmer, Inez Johanna, Zsolt Sebestyen, Jurgen Kuball, Trudy Straetemans

Blood (2022) 140 (Supplement 1): 12737–12739.

https://doi.org/10.1182/blood-2022-158191

Published: 2022

Journal Articles

Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation for Therapy-Related Myeloid Neoplasms Following Treatment for Myeloma

Blood (2022) 140 (Supplement 1): 4884–4885.

https://doi.org/10.1182/blood-2022-169326

Published: 2022

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm Following Treatment for Lymphoma: A Study of the Chronic Malignancies Working Party of the EBMT

Blood (2022) 140 (Supplement 1): 10547–10549.

https://doi.org/10.1182/blood-2022-162546

Published: 2022

Journal Articles

Handling of Allogeneic HPC Grafts in European Transplant Centers during the COVID-19 Pandemic - a Survey from the Infectious Diseases and Cellular Therapy & Immunobiology Working Parties of the EBMT

Nina Worel, Per T Ljungman, Isabel Sánchez-Ortega, Jorinde D Hoogenboom, Nina S Knelange, Inge CM Verheggen, Dirk-Jan Eikema, Annalisa Ruggeri, Jurgen Kuball, Diana Averbuch, Rafael De La Camara, Christian Chabannon

Blood (2022) 140 (Supplement 1): 10439–10440.

https://doi.org/10.1182/blood-2022-165383

Published: 2022

Journal Articles

Long-Term Outcome of Second Allogeneic Stem Cell Transplantation (HSCT2) for Primary Graft Failure in Patients with Acute Leukemia in Remission: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Arnon Nagler, Myriam Labopin, Alexander D. Kulagin, Andrea Velardi, Jaime Sanz, Hélène Labussière-Wallet, Victoria Potter, Jurgen Kuball, Simona Sica, Elena N. Parovichnikova, Wolfgang Bethge, Xavier Leleu, Uwe Platzbecker, Friedrich Stölzel, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 7578–7579.

https://doi.org/10.1182/blood-2022-156231

Published: 2022

Journal Articles

Activity of Ex Vivo Graft and DLI Engineering within the Last Decade Increases, a Survey from the EBMT Cellular Therapy & Immunobiology Working Party

Moniek de Witte, Jorinde Hoogenboom, Jarl Mooyaart, Christian Chabannon, Florent Malard, Annalisa Ruggeri, Jurgen Kuball

Blood (2022) 140 (Supplement 1): 4741–4742.

https://doi.org/10.1182/blood-2022-157422

Published: 2022

Journal Articles

CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Large Real-World Series from Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Blood (2022) 140 (Supplement 1): 10389–10390.

https://doi.org/10.1182/blood-2022-158880

Published: 2022

Journal Articles

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

Blood (2019) 133 (13): 1457–1464.

https://doi.org/10.1182/blood-2018-10-879866

Published: 2019

Includes: Supplemental data

Journal Articles

Results of a Prospective, Multicenter, Phase I/II Clinical Study in Pediatric and Adult Patients Using TCR Alpha/Beta and CD19 Depleted Haploidentical Hematopoietic Stem Cell Grafts Following Reduced-Intensity Conditioning

Blood (2018) 132 (Supplement 1): 604.

https://doi.org/10.1182/blood-2018-99-110124

Published: 2018

Journal Articles

First Results of a Prospective I/II Clinical Trial in Adult Patients Using TCR Alpha/Beta Depleted Stem Cell Transplantation from Matched Related and Unrelated Donors

Moniek De Witte, MD PhD, Anna Van Rhenen, MD PhD, Geerte Van Sluis, MD PhD, Rick Admiraal, MD PhD, Lotte van der Wagen, MD, Eefke J. Petersen, MD PhD, Reinier Raymakers, MD PhD, Monique C Minnema, MD PhD, Anke Janssen, MD, Kasper Westinga, BSc, Constantijn J.M. Halkes, MD, J.H. Frederik Falkenburg, MD PhD, Jaap Jan Boelens, MD PhD, Jurgen Kuball, MD

Blood (2018) 132 (Supplement 1): 2164.

https://doi.org/10.1182/blood-2018-99-112758

Published: 2018

Journal Articles

Towards the Next Generation CAR T Cells with TEGs: In Vivo Efficacy — Toxicity Profile in Xenografts of Primary Human AML Disease and Healthy Bone Marrow

Trudy Straetemans, PhD, Inez Johanna Gan, MSc, Sabine Heijhuurs, MSc, Guido Kierkels, MSc, Koen Jansen, BSc, Ruud Doorn, BSc, Tineke Aarts, BSc, Haakan Norrel, PhD, Zsolt Sebestyen, PhD, Jurgen Kuball, MD

Blood (2017) 130 (Supplement 1): 3336.

https://doi.org/10.1182/blood.V130.Suppl_1.3336.3336

Published: 2017

Journal Articles

First Results of a Prospective Multicenter Phase I/II Clinical Trial in Adult Patients Using Tcralpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning

Wolfgang Bethge, MD, Stephan Mielke, MD, Dietger Niederwieser, MD, Roland Meisel, MD, Donald w. Bunjes, MD, Arne Brecht, MD, Jurgen Kuball, MD, Sandra Karitzky, PhD, Silke Holtkamp, Christiane Siewert, PhD, Stefanie Pflitsch, Michael Schumm, DVM, Matthias K. Eyrich, MD, Vladan Vucinic, Markus Wiesneth, MD, Kasper Westinga, Rupert Handgretinger, MD PhD

Blood (2017) 130 (Supplement 1): 213.

https://doi.org/10.1182/blood.V130.Suppl_1.213.213

Published: 2017

Journal Articles

Efficacy of Bone Marrow Derived MSC for Steroid Refractory Acute GVHD Associates with Age and a Defined Molecular Profile of MSC Donors

Lotte van der Wagen, MD, Febilla Fernando, Nagesha Appukudige, PhD, Anke Janssen, MD, Kasper Westinga, Rick Admiraal, MD PhD, Magdalena Lorenowicz, PhD, Paul J. Coffer, PhD Prof, Sacha Zeerleder, PhDMD, Jeroen J. Janssen, MD PhD, Gerwin Huls, MD PhD, Annoek Broers, MD PhD, Walter JFM Van Der Velden, Marinus van Marwijk Kooij, MD PhD, Jaap Jan Boelens, MD PhD, Ineke Slaper-Cortenbach, PhD, Jurgen Kuball, MD

Blood (2017) 130 (Supplement 1): 1929.

https://doi.org/10.1182/blood.V130.Suppl_1.1929.1929

Published: 2017

Journal Articles

Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (≥ 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)

Geert Huls, MD PhD, Dana Chitu, Violaine Havelange, Mojca Jongen-Lavrencic, MD PhD, Arjen van de Loosdrecht, Bart J. Biemond, MD PhD, Harm Sinnege, MDPhD, Beata Hodossy, Carlos Graux, Marinus van Marwijk Kooij, MD PhD, Okke de Weerdt, MD, Dimitri Breems, MD PhD, Saskia Klein, MD, Jurgen Kuball, MD, Gert J. Ossenkoppele, MD PhD, Bob Lowenberg, MD PhD, Edo Vellenga, MD

Blood (2017) 130 (Supplement 1): 463.

https://doi.org/10.1182/blood.V130.Suppl_1.463.463

Published: 2017

Journal Articles

Nicord Single Unit Expanded Umbilical Cord Blood Transplantation: Final Results of a Multicenter Phase I/ II Trial

Mitchell E. Horwitz, MD, Daniela Cilloni, MD, David Valcarcel, Francesco Frassoni, MD, Jaap Jan Boelens, MD PhD, Madan Jagasia, MD MBBS, MS, John E. Wagner, MD, Jurgen Kuball, MD, Liang Piu Koh, Navneet S. Majhail, MD MS, Patrick J. Stiff, MD, Rabi Hanna, MD, Richard Thomas T. Maziarz, MD, William YK Hwang, MBBS, FRCP, Pau Montesinos, MD PhD, Joanne Kurtzberg, MD, Guillermo Sanz, MD

Blood (2017) 130 (Supplement 1): 847.

https://doi.org/10.1182/blood.V130.Suppl_1.847.847

Published: 2017

NARROW

A Novel Prognostic Model for Patients with Acute Myeloid Leukemia in First Relapse with Improved Prognostic Accuracy

Allogeneic Hematopoietic Cell Transplantation for Vexas Syndrome: Results of a Multicenter Study from the Chronic Malignancies and Autoimmune Disease Working Parties of the EBMT

Interindividual HLA Evolutionary Divergence in Single HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation for Malignant Hematological Disorders: A Report on Behalf of the Cellular Therapy and Immunobiology Working Party of the EBMT

Improved Gvhd-Relapse Free Survival of Ex Vivo αβtcr/CD19 Depleted Allo-Sct Combined with In Vivo T Cell Depletion with ATG When Compared to T Cell Replete Transplantations with or without the Addition of ATG

Long Term Outcomes and Renal Response Following Autologous Stem Cell Transplantation for Light Chain Deposition Disease:a Retrospective Study on Behalf of the Cmwp of the EBMT

First in Human Clinical Responses and Persistence Data on TEG001: A Next Generation of Engineered Αβ T Cells Targeting AML and MM with a High Affinity γ9δ2TCR

Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation for Therapy-Related Myeloid Neoplasms Following Treatment for Myeloma

Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm Following Treatment for Lymphoma: A Study of the Chronic Malignancies Working Party of the EBMT

Handling of Allogeneic HPC Grafts in European Transplant Centers during the COVID-19 Pandemic - a Survey from the Infectious Diseases and Cellular Therapy & Immunobiology Working Parties of the EBMT

Long-Term Outcome of Second Allogeneic Stem Cell Transplantation (HSCT2) for Primary Graft Failure in Patients with Acute Leukemia in Remission: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Activity of Ex Vivo Graft and DLI Engineering within the Last Decade Increases, a Survey from the EBMT Cellular Therapy & Immunobiology Working Party

CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Large Real-World Series from Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

Results of a Prospective, Multicenter, Phase I/II Clinical Study in Pediatric and Adult Patients Using TCR Alpha/Beta and CD19 Depleted Haploidentical Hematopoietic Stem Cell Grafts Following Reduced-Intensity Conditioning

First Results of a Prospective I/II Clinical Trial in Adult Patients Using TCR Alpha/Beta Depleted Stem Cell Transplantation from Matched Related and Unrelated Donors

Towards the Next Generation CAR T Cells with TEGs: In Vivo Efficacy — Toxicity Profile in Xenografts of Primary Human AML Disease and Healthy Bone Marrow

First Results of a Prospective Multicenter Phase I/II Clinical Trial in Adult Patients Using Tcralpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning

Efficacy of Bone Marrow Derived MSC for Steroid Refractory Acute GVHD Associates with Age and a Defined Molecular Profile of MSC Donors

Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (≥ 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)

Nicord Single Unit Expanded Umbilical Cord Blood Transplantation: Final Results of a Multicenter Phase I/ II Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only